世界卫生组织《结核分枝杆菌耐药相关基因突变目录(第2版)》解读OA北大核心CSTPCD

Drug-resistant tuberculosis is a major obstacle to the achievement of the End TB Strategy by 2035.The World Health Organization(WHO)promotes the use of rapid molecular drug susceptibility testing technology for early diagnosis of drug-resistant tuberculosis.Covering comprehensive and reliable drug resistance-related mutations is the key to improving the reliability of molecular drug resistance diagnosis.WHO has released the second edition of the Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance in November 2023.This catalogue described more comprehensive and accurate drug-resistance-related gene mutations based on the largest collection of multinational Mycobacterium tuberculosis complex isolates,so as to support the development and improvement of the molecular drug susceptibility testing technology.This article provides a detailed interpretation of the updates in the analysis process and drug-resistant mutations in the second edition of the catalogue compared with the first edition,and looks forward to the future direction of improving the catalogue.